Creyon Bio is a pioneering pre-clinical firm revolutionizing oligonucleotide-based drug development for on-demand medicines. The company focuses on reimagining drug development from discovery to engineering, utilizing powerful, purpose-built data sets to drive the creation of machine learning models. This enables the engineering of oligonucleotide-based medicines (OBMs) for safe, precise gene-centric therapies with unprecedented speed and predictable efficacy and safety.
Creyon Bio has achieved significant milestones in the field of drug development by leveraging a groundbreaking modular approach. This innovative strategy allows for the efficient and rapid creation of OBMs, positioning the company as a leader in the development of gene-centric therapies. The impact of Creyon Bio's work is evident in its ability to produce safe and effective treatments with a high degree of precision, setting new standards in the pharmaceutical industry.
